Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 375; no. 3; pp. 469 - 477
• Main Authors: Baehr, Carly, Kelcher, April Huseby, Khaimraj, Aaron, Reed, Dana E., Pandit, Sujata G., AuCoin, David, Averick, Saadyah, Pravetoni, Marco
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2020; The American Society for Pharmacology and Experimental Therapeutics
• Subjects: Analgesics, Opioid - immunology; Analgesics, Opioid - toxicity; Animals; Antibodies, Monoclonal - immunology; Behavior, Animal; Drug Discovery and Translational Medicine; Female; Immunization; Male; Mice; Rats; Ab; sKLH; F; HRP; IL-4; M; mAb; GC-MS; BSA; OXY; LC-MS; PE; 6-AM; BLI; OUD
• ISSN: 0022-3565; 1521-0103; 1521-0103
• DOI: 10.1124/jpet.120.000124

Monoclonal antibodies (mAbs) and vaccines have been proposed as medical countermeasures to treat opioid use disorder (OUD) and prevent opioid overdose. In contrast to current pharmacotherapies (e.g., methadone, buprenorphine, naltrexone, and naloxone) for OUD and overdose, which target brain opioid receptors, mAbs and vaccine-generated polyclonal antibodies sequester the target opioid in the serum and reduce drug distribution to the brain. Furthermore, mAbs offer several potential clinical benefits over approved medications, such as longer serum half-life, higher selectivity, reduced side effects, and no abuse liability. Using magnetic enrichment to isolate opioid-specific B cell lymphocytes prior to fusion with myeloma partners, this study identified a series of murine hybridoma cell lines expressing mAbs with high affinity for opioids of clinical interest, including oxycodone, heroin and its active metabolites, and fentanyl. In mice, passive immunization with lead mAbs against oxycodone, heroin, and fentanyl reduced drug-induced antinociception and the distribution of the target opioid to the brain. In mice and rats, mAb pretreatment reduced fentanyl-induced respiratory depression and bradycardia, two risk factors for opioid-related overdose fatality. Overall, these results support use of mAbs to counteract toxic effects of opioids and other chemical threats. The incidence of fatal overdoses due to the widespread access to heroin, prescription opioids, and fentanyl suggests that current Food and Drug Administration–approved countermeasures are not sufficient to mitigate the opioid epidemic. Monoclonal antibodies (mAbs) may provide acute protection from overdose by binding to circulating opioids in serum. Use of mAbs prophylactically, or after exposure in combination with naloxone, may reduce hospitalization and increase survival.